Syros Pharmaceuticals, Inc.
Syros is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is developing tamibarotene, an oral selective RARĪ± agonist in frontline patients with higher-risk myelodysplastic syndrome with RARA gene overexpression.
Syros Pharmaceuticals
Karen Hunady
Director of Corporate Communications & Investor Relations
khunady@syros.com
Precision AQ Investor Relations, Inc.
Amanda Isacoff
amanda.isacoff@precisionaq.com
Computershare Trust Company, N.A.